Taiyen Biotech Co Ltd - Asset Resilience Ratio
Taiyen Biotech Co Ltd (1737) has an Asset Resilience Ratio of 4.73% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Taiyen Biotech Co Ltd (1737) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2025)
This chart shows how Taiyen Biotech Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Taiyen Biotech Co Ltd.
Liquid Assets Composition Over Time
This chart breaks down Taiyen Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Taiyen Biotech Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$396.29 Million | 4.73% |
| Total Liquid Assets | NT$396.29 Million | 4.73% |
Asset Resilience Insights
- Limited Liquidity: Taiyen Biotech Co Ltd maintains only 4.73% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Taiyen Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Taiyen Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Colgate Palmolive (India) Limited
NSE:COLPAL |
Household & Personal Products | 49.03% |
|
Guangdong Marubi Biotechnology Co
SHG:603983 |
Household & Personal Products | 8.42% |
|
C&S Paper Co Ltd
SHE:002511 |
Household & Personal Products | 8.72% |
|
Chongqing Baiya Sanitary Products Co
SHE:003006 |
Household & Personal Products | 9.52% |
|
Leifheit Aktiengesellschaft
F:LEI |
Household & Personal Products | 6.37% |
|
Mcphersons Ltd
AU:MCP |
Household & Personal Products | 10.94% |
|
Rigolleau SA
BA:RIGO |
Household & Personal Products | 0.27% |
|
ZOONO Group Ltd
AU:ZNO |
Household & Personal Products | 9.18% |
Annual Asset Resilience Ratio for Taiyen Biotech Co Ltd (2003–2025)
The table below shows the annual Asset Resilience Ratio data for Taiyen Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.80% | NT$396.40 Million ≈ $12.49 Million |
NT$8.26 Billion ≈ $260.32 Million |
+0.18pp |
| 2024-12-31 | 4.61% | NT$386.62 Million ≈ $12.18 Million |
NT$8.38 Billion ≈ $264.05 Million |
-0.13pp |
| 2023-12-31 | 4.75% | NT$394.85 Million ≈ $12.44 Million |
NT$8.32 Billion ≈ $262.12 Million |
+0.38pp |
| 2022-12-31 | 4.36% | NT$358.12 Million ≈ $11.28 Million |
NT$8.21 Billion ≈ $258.71 Million |
+0.13pp |
| 2021-12-31 | 4.23% | NT$358.00 Million ≈ $11.28 Million |
NT$8.47 Billion ≈ $266.78 Million |
-0.71pp |
| 2020-12-31 | 4.94% | NT$384.97 Million ≈ $12.13 Million |
NT$7.80 Billion ≈ $245.67 Million |
+0.04pp |
| 2019-12-31 | 4.90% | NT$372.24 Million ≈ $11.73 Million |
NT$7.60 Billion ≈ $239.49 Million |
-1.85pp |
| 2018-12-31 | 6.75% | NT$494.41 Million ≈ $15.58 Million |
NT$7.33 Billion ≈ $230.81 Million |
-0.29pp |
| 2017-12-31 | 7.03% | NT$509.78 Million ≈ $16.06 Million |
NT$7.25 Billion ≈ $228.32 Million |
-2.37pp |
| 2016-12-31 | 9.40% | NT$663.16 Million ≈ $20.89 Million |
NT$7.05 Billion ≈ $222.22 Million |
-3.06pp |
| 2015-12-31 | 12.46% | NT$853.62 Million ≈ $26.89 Million |
NT$6.85 Billion ≈ $215.85 Million |
-0.16pp |
| 2014-12-31 | 12.62% | NT$850.13 Million ≈ $26.78 Million |
NT$6.74 Billion ≈ $212.29 Million |
+0.55pp |
| 2013-12-31 | 12.06% | NT$744.54 Million ≈ $23.46 Million |
NT$6.17 Billion ≈ $194.43 Million |
+2.14pp |
| 2012-12-31 | 9.92% | NT$681.69 Million ≈ $21.48 Million |
NT$6.87 Billion ≈ $216.39 Million |
-2.20pp |
| 2011-12-31 | 12.12% | NT$844.45 Million ≈ $26.60 Million |
NT$6.97 Billion ≈ $219.47 Million |
+0.10pp |
| 2010-12-31 | 12.02% | NT$835.39 Million ≈ $26.32 Million |
NT$6.95 Billion ≈ $218.98 Million |
+4.98pp |
| 2009-12-31 | 7.03% | NT$485.14 Million ≈ $15.28 Million |
NT$6.90 Billion ≈ $217.29 Million |
-7.70pp |
| 2008-12-31 | 14.74% | NT$982.08 Million ≈ $30.94 Million |
NT$6.66 Billion ≈ $209.96 Million |
-7.81pp |
| 2007-12-31 | 22.55% | NT$1.58 Billion ≈ $49.72 Million |
NT$7.00 Billion ≈ $220.53 Million |
+22.28pp |
| 2006-12-31 | 0.26% | NT$19.74 Million ≈ $621.98K |
NT$7.46 Billion ≈ $235.00 Million |
-27.96pp |
| 2005-12-31 | 28.23% | NT$2.21 Billion ≈ $69.60 Million |
NT$7.83 Billion ≈ $246.56 Million |
-7.72pp |
| 2004-12-31 | 35.95% | NT$3.54 Billion ≈ $111.42 Million |
NT$9.84 Billion ≈ $309.93 Million |
-5.24pp |
| 2003-12-31 | 41.19% | NT$4.73 Billion ≈ $149.12 Million |
NT$11.49 Billion ≈ $362.04 Million |
-- |
About Taiyen Biotech Co Ltd
Taiyen Biotech Co., Ltd. engages in the production and sale of salt products in Taiwan and internationally. It offers seawater chemicals; toothpaste, mouthwashes, and eyeglass solutions; beverages; bottled water; medical supplies; food and food additives; beauty, skincare, and cleaning products; and salt products; as well as health food and health products. The company was founded in 1952 and is … Read more